江湖电竞网站登陆在线
MRNA
US
$
-0.09
-0.06%
After Hours
$
142.19
After Hours Volume:
146.77K
| Close | Chg | Chg % |
|---|---|---|
| $142.28 | 1.00 | 0.71% |
Volume: 3.5M
65 Day Avg: 4.95M
138.06
Day Range
142.65
115.61
52 Week Range
464.85
Overview
MRNA Overview
Key Data
- Open $142.04
- Day Range 138.06 - 142.65
- 52 Week Range 115.61 - 464.85
- Market Cap $55.27B
- Shares Outstanding 391.2M
- Public Float 337.34M
- Beta 0.55
- Rev. per Employee $8.475M
- P/E Ratio 4.34
- EPS $32.80
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 14.98M 08/15/22
- % of Float Shorted 4.44%
- Average Volume 4.95M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
19
Full Ratings
Recent News
Biotech and Pharma Moderna Wants Investors to Look Past Its Covid-19 Vaccine
Moderna upgraded to buy from hold at Deutsche Bank
Moderna's omicron-targeted booster vaccine authorized by Health Canada
Moderna (MRNA) Gains But Lags Market: What You Should Know
Moderna (MRNA) closed the most recent trading day at $142.33, moving +0.74% from the previous trading session.
on Zacks.com
Peering Into Moderna's Recent Short Interest
on Benzinga.com
Stock Market News for Sep 9, 2022
Wall Street closed higher on Thursday, led by a rally in finance and healthcare stocks.
on Zacks.com
Why Moderna Stock Triumphed on Thursday
on Motley Fool
Brookline Capital Markets Sticks to Their Buy Rating for Moderna (MRNA)
Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna (MRNA - Research Report) today and set a price target of $506.00. The company's shares closed today at $141.28.R. Cann covers the Healthcare...
on TipRanks.com
Check Out What Whales Are Doing With MRNA
on Benzinga.com
What To Know About Deutsche Bank's Upgrade of Moderna
on Benzinga.com
4 Analysts Have This to Say About Moderna
on Benzinga.com
2 Top Healthcare Stocks to Buy for September
on Motley Fool
Moderna To $165? Plus This Analyst Cuts PT On FedEx
on Benzinga.com
Where Moderna Stands With Analysts
on Benzinga.com
Why Moderna Stock Slumped Today
on Motley Fool
Why Novavax Stock Sank to a New 52-Week Low Today
on Motley Fool
Shifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, Pfizer
Shifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, Pfizer
on GuruFocus.com
3 Robinhood Stocks to Buy Right Now
on Motley Fool
Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland
Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.
on Zacks.com
Moderna Inc.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Johnson & Johnson |
|
$434.84B |
| Pfizer Inc. |
|
$264.23B |
| AstraZeneca PLC ADR |
|
$187.14B |
| AstraZeneca PLC |
|
£162.88B |
| GSK PLC |
|
£54.35B |
| Gilead Sciences Inc. |
|
$81.59B |
| BioNTech SE ADR |
|
$35.72B |
| Regeneron Pharmaceuticals Inc. |
|
$77.27B |
| Biogen Inc. |
|
$30.18B |
| CureVac N.V. |
|
$1.8B |